Susheel K. Kodali, MD

Trial in progress: Neoadjuvant combination therapy of lenvatinib plus transcatheter arterial chemoembolization (TACE) for transplant-eligible patients with large hepatocellular carcinoma

Background Hepatocellular carcinoma HCC is the third leading cause of cancer death worldwide with more than 230,000 cases of HCC since 2000 and an estimated 42,000 new c...

A. Esmail ;

A. Saharia ;

Susheel K. Kodali , MD;

D. Victor ;

K. Heyne ;

R. Ghobrial ;

M. Abdelrahim ;

06/27/2022

Atezolizumab and bevacizumab pre-liver transplantation for patients with hepatocellular carcinoma beyond Milan criteria

Background Hepatocellular carcinoma (HCC) represents the second most common cause of cancer-related death and accounts for over 80% of primary liver cancers worldwide. C...

M. Abdelrahim ;

A. Esmail ;

A. Saharia ;

Susheel K. Kodali , MD;

D. Victor ;

G. OKane ;

06/27/2022

Leaflet Modification

The ShortCut Pivotal Trial: A Dedicated Valve Leaflet Splitting Device

10/25/2023

Susheel K. Kodali , MD;

The ShortCut leaflet splitting procedure can be done in anywhere from five to 10 minutes, says Dr. Susheel Kodali, and patients typically remain stable during the procedure.

The ShortCut leaflet splitting...

10/25/2023

Cath Lab Digest

Clinical Editor's Corner

TAVR: Who Should Prep the Device? The Role of Industry Representatives’ Participation in the Cath Lab

01/03/2022

Christopher J. White , DO, MD;

Morton J. Kern , MD, MSCAI, FACC, FAHA;

Michael Ragosta , MD;

David J. Cohen , MD, MPH, MSc;

Ramon Quesada , MD, FACP, FACC, FSCAI;

Susheel K. Kodali , MD;

Stephen R. Ramee , MD;

Samuel M. Butman , MD;

Amir Kaki , MD, FACC, FSCAI;

Duane S. Pinto , MD, MPH;

William F. Fearon , MD;

Mauricio G. Cohen , MD, FACC;

Robert J. Applegate , MD;

Aaron V. Kaplan ;

David G. Rizik , MD, FACC, FSCAI;

Jeffrey Marshall ;

Bonnie H. Weiner , MD, MBA, FSCAI, FACC;

After years of having the industry clinical support staff prep the transcatheter aortic valve replacement (TAVR) valves in the lab (without a single adverse event because of faulty prep, to my knowledge) some administrators have now begun to...

After years of having the...

01/03/2022

Cath Lab Digest

Clinical Images

Endovascular eSheath Predilation to Facilitate Transfemoral Transcatheter Aortic Valve Delivery

05/01/2022

Susheel K. Kodali , MD;

Torsten P. Vahl , MD;

Isaac George , MD;

Tamim M. Nazif , MD;

Nino Mihatov , MD;

Peripheral artery disease (PAD) is common among patients undergoing transfemoral (TF) transcatheter aortic valve replacement (TAVR) and is associated with worse outcomes.1 Criteria for unfavorable TF anatomy include small-diameter vessels and...

Peripheral artery disease (PAD)...

05/01/2022

Journal of Invasive Cardiology

Video

Endovascular eSheath Predilation to Facilitate Transfemoral TAVR

05/01/2022

Susheel K. Kodali , MD;

Torsten P. Vahl , MD;

Isaac George , MD;

Tamim M. Nazif , MD;

Nino Mihatov , MD;

Angiographic series demonstrating endovascular eSheath balloon dilation to facilitate transcatheter valve delivery.

Angiographic series...

05/01/2022

Journal of Invasive Cardiology

Urologic Complications in Patients Receiving Indwelling Urinary Catheters During Transcatheter Aortic Valve Replacement

07/01/2020

Alex Kantor , BS ;

Deniz Akkoc , BS ;

Shmuel Chen , MD, PhD;

Russel Brandwein , PA-C;

Kathryn Fidlow , BSN;

Ming Liao , MS;

Martin B. Leon , MD;

Omar Khalique , MD;

Susheel K. Kodali , MD;

Rebecca T. Hahn , MD;

Torsten P. Vahl , MD;

Isaac George , MD;

Tamim M. Nazif , MD;

Ajay J. Kirtane , MD, SM;

Joshua A. Lampert , MD;

Matthew T. Finn , MD, MS;

The minimalist approach to transcatheter aortic valve replacement (TAVR) focuses on avoiding extraneous invasive measures. Data describing the clinical impact of routine indwelling urinary catheter in TAVR patients are limited. We sought to...

The minimalist approach to...

07/01/2020

Journal of Invasive Cardiology